fig1

Overcoming immunotherapy resistance in pMMR/MSS colorectal cancer: multi-target combination strategies

Figure 1. Multi-layered mechanisms driving primary resistance to immune checkpoint inhibitors in pMMR/MSS colorectal cancer. Tumor-intrinsic mechanisms (left panel) include Wnt/β-catenin activation driving T cell exclusion (suppressed CCL4 and Batf3-lineage dendritic cell exclusion); a distinct tumor-intrinsic NOTUM program that inhibits Wnt signaling yet drives immune resistance; metabolic reprogramming (lactate accumulation, methionine-PCSK9 axis, PSAT1-GPX4-mediated ferroptosis resistance); antigen presentation defects (PTEN loss-mediated MHC-I degradation, cathepsin D activity, low TMB); and oncogenic drivers (BRAF V600E, KRAS, ERBB2/HER2). Microenvironmental mechanisms (right panel) encompass immune checkpoint upregulation (LAG-3, TIM-3, TIGIT, CD160), immunosuppressive TME components (M2 TAMs, PMN-MDSCs, Tregs, CAFs, TGF-beta), gut microbiota dysbiosis (F. nucleatum enrichment, 4-HPA-mediated MDSC accumulation), and stromal barriers (SPP1-stimulated CXCL12 production by CAFs generating a T cell-sequestering chemokine gradient). These mechanisms converge to create an immune-cold TME characterized by low CD8+ TIL infiltration, high Treg/MDSC abundance, exhausted T cell phenotype, and primary resistance to ICIs.